Glaukos Co. (NYSE:GKOS) Director Sells $392,010.00 in Stock

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $126.28 on Friday. The company has a market capitalization of $6.94 billion, a P/E ratio of -43.85 and a beta of 1.03. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $136.60. The firm’s 50 day simple moving average is $124.45 and its two-hundred day simple moving average is $109.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company’s revenue was up 19.0% on a year-over-year basis. During the same period last year, the firm earned ($0.55) EPS. Research analysts expect that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Glaukos

A number of hedge funds have recently made changes to their positions in the business. National Bank of Canada FI bought a new position in shares of Glaukos during the fourth quarter worth $46,000. Quadrant Capital Group LLC boosted its holdings in shares of Glaukos by 54.8% during the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after purchasing an additional 329 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 486 shares in the last quarter. Caldwell Sutter Capital Inc. increased its holdings in shares of Glaukos by 5,860.0% in the first quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 1,465 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC purchased a new stake in shares of Glaukos in the second quarter worth about $187,000. Institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on GKOS shares. Morgan Stanley boosted their target price on shares of Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Stifel Nicolaus upped their price objective on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Needham & Company LLC raised their target price on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company upped their price target on shares of Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Finally, BTIG Research raised their price objective on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.82.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.